Hypofractionated radiation therapy
Hypofractionated radiation therapy is a radiation therapy with 84 clinical trials. Currently 44 active trials ongoing. Historical success rate of 71.9%.
Success Metrics
Based on 23 completed trials
Phase Distribution
Phase Distribution
13
Early Stage
38
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
65.7%
23 of 35 finished
34.3%
12 ended early
44
trials recruiting
84
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
SMC Radiation Oncology Breast Cancer Cohort Study
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
Clinical Trials (84)
SMC Radiation Oncology Breast Cancer Cohort Study
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 84